

وَاتَّقُوا اللَّهَ صَلَّوَيُعَلِّمُكُمُ اللَّه

Bronchial Asthma

BY

Dr. Haggagy Mansour


Lecturer of Chest Diseases

South-Vally University

Part 1 INTRODUCTION ANATOMY & PHYSIOLOGY

WHAT IS RESPIRATORY SYSTEM?

- The respiratory system (also respiratory apparatus, ventilatory system) is a biological system, consisting of specific organs and structures used for gas exchange in human.
- Organs of Respiratory System:
- Nose and nasal cavity.
- Pharynx
- Larynx
- Trachea
- Two bronchi
- Bronchioles
- Two Lungs



TRACHEA

- Position
- The trachea or windpipe is a continuation of the larynx & extends downwards to about the level of T-5 where it divides into right & left primary bronchi.
- Length-10-11cm
- Relation

Superiorly-the larynx


Inferiorly-the right & left bronchi

Anteriorly-upper part-the thyroid gland.

lower part-the arch of aorta & the sternum.

Posteriorly-.the oesophagus

Laterally- the lungs



STRUCTURE

- Composed of 3 layers of tissue.
- (i) fibrous & elastic tissue
- (ii) smooth muscle
- (iii) ciliated columnar epithelium
- Held open by between 16-20 incomplete cartilage rings (C-shaped)

Blood supply

Inferior thyroid artery


Bronchial artery

Venous drainage

Inferior thyroid veins

Nerve supply

Laryngeal nerve



FUNCTIONS


- Support and patency
- Mucociliary escalator
- Cough reflex
- Warming
- Humidifying
- Filtering


BRONCHI & BRONCHIOLES

- The two primary bronchi when the trachea divides about the level of T-5.
- The right bronchus
- This is wider, shorter and more vertical than the left bronchus.
- Length-2.5cm
- After entering the right lung, it divides into 3 branches, one to each lobe.
- The left bronchus
- This is narrower than the right
- Length-5cm
- After entering the left lung, it divides into 2 branches, one to each lobe.



Note:





STRUCTURE

- The bronchi are composed of the same issues as the trachea.
- Are lined with **ciliated columnar epithelium.**

Division of bronchi


Bronchioles

Terminal bronchioles

Respiratory bronchioles

Alveolar ducts

Alveoli




- The wider passages are called conducting airways
- Conducting airways, bring air into the lungs & their walls are too thick to permit gas exchange.
- Blood supply
- Bronchial arteries
- Venous drainage
- Bronchial veins
- Nerve supply
- Vagus nerve
- Lymph drainage
- The Thoracic duct

FUNCTIONS

- Control of air entry
- Warming & humidifying
- Support & patency
- Removal of particulate matter
- Cough reflex

RESPIRATORY BRONCHIOLES & ALVEOLI

- Each lobule is supplied with air by a terminal bronchiole
- Which further subdivides into respiratory bronchioles, alveolar ducts and large numbers of alveoli (air sacs)
- About 150 million alveoli in the adult lung
- In these structures that the process of gas exchange occurs.
- As airways progressively divide & become smaller & smaller, their walls gradually become thinner.
- These distal respiratory passages are supported by a loose network of elastic connective tissue.
- Exchange of gases in the lungs takes place in alveoli



RESPIRATION

- The term respiration means the exchange of gases between body cells and the environment.
- Breathing or pulmonary ventilation
- This is movement of air into and out of the lungs.
- Exchange of gases:
- This takes place:
- In the lungs:external respiration.
- In the tissues:internal respiration.

BREATHING

- Breathing supplies oxygen to the alveoli, and eliminates carbon dioxide.
- MUSCLES OF BREATHING
- Expansion of the chest during inspiration occurs as a result of muscular activity, partly voluntary and partly involuntary.
- The main muscles used in normal quiet breathing are the INTERCOSTAL MUSCLES and the DIAPHRAGM.
- During difficult or deep breathing they are assisted by muscles of the neck, shoulders and abdomen.

Part 2 BRONCHIALASTHMA

Definition

Bronchial asthma is a chronic inflammatory disease of airways, preferably of allergic genesis, characterised by reversible airway obstruction, increased airway responsiveness to a variety of stimuli - bronchial hyperresponsiveness, and manifested by asthma episodic wheezing, feeling tightness in the chest, dyspnea and cough (dry or productive with expectoration of mucous viscous sputum).

Causes:

- Asthma is caused by a combination of complex and incompletely understood environmental and genetic interactions.
- Environmental: allergens, pollens, air pollution & other chemicals.
- Smoking
- Chemical exposure(formaldehyde, pesticides)
- Use of antibiotics in early life
- ▶ Genetic


Bronchial asthma Classifications

Asthma may be categorized into types

- 1- Atopic type (allergic sensitization Extrinsic).
- 2 Non-atopic type (No allergic sensitization).
- 3- Bronchoconstriction triggering agents include
- (a) <mark>Seasonal</mark> asthma (b) Exercise-induced asthma.
- (c) Drug-induced asthma (e.g., aspirin & NSAID).
 (d) Occupational asthma
 (e) Eemotional asthma.

-) Asthmatic bronchitis in smokers.

4-Recent studies added three subphenotypes of Asthma, based on Airway inflammation pattern.



Asthma Types


- 1- Atopic asthma (allergic sensitization, Extrinsic) :
- Classic example of type I IgE-mediated hypersensitivity reaction.
- Usually encountered in patient known case of rhinitis, eczema.
- Genetic predisposition.
- A positive family history of asthma is common.
- Begins in childhood.
- Triggered by environmental allergens, such as dusts, pollens, roach or animal dander, and certain types of foods., etc...
- <u>Diagnosis</u>: clinical diagnosis is essential +.....
- (a) Skin test: Using the offending antigen

 immediate wheal-and-flare reaction.
- (b) Serum radioallergosorbent tests (called RAST): TO identify the presence of IgE specific for a panel of allergens.


Asthma Types

- 2. Non-atopic asthma:
 - Non allergic.
 - Triggered commonly > by Respiratory infection due to viruses (e.g., rhinovirus, parainfluenza virus).
 - Family history: less common.
 - Skin test: reveals negative reaction.
 - Mechanism:


It is thought that virus-induced inflammation of the respiratory mucosa → lowers the threshold of the subepithelial vagal receptors to irritants.



TRIGGERS








Symptoms

- Shortness of breath Rapid, shallow
- Wheezing
- Difficult breathing
- Cough
- Anxiety

Physical findings

- Rapid, shallow respirations
- Rapid pulse
- Pallor or cyanosis
- Diminished breath sounds
- Generalized retractions
- Frequent pausing to catch the breath when talking
- Hyperexpansion of the chest

ASTHMA



Classification	Symptoms	Treatment
Mild Intermittent	Daytime: <_ 2/wk HS: <_2/month Asymptomatic or normal PEF between brief exacerbations Lung fnx: FEV1 or PEF >_ 80% & variability < 20%	No daily medication Bronchodilators prn symptoms (short-acting inhaled B2 agonist) – use as needed
Mild Persistent	Daytime: > 2 wk but < 1/day QHS: > 2/month Lung fnx: FEV1 or PEF > 80%; PEF variability 20- 30%	Daily: low dose inhaled corticosteroid Bronchodilator prn symptoms (short-acting B2 agonist)
Moderate Persistent	Daytime: daily symptoms & daily use of inhaled short-acting B2 agonists QHS: > 1/wk Exacerbations > 2/week Lung fnx: FEV1 or PEF 60-79% PEF variability > 30%	Low dose corticosteroids & long-acting B2 agonist -OR-Medium dose corticosteroids Bronchodilator prn symptoms (short-acting B2 agonist)
Severe Persistent	Daytime: continual symptoms with limited physical activity Frequent QHS symptoms & frequent exacerbations Lung fnx: FEV1 or PEF ≤ 60 % PEF variability > 30%	High dose inhaled corticosteroids & long-acting B2 agonist +/- Corticosteroids PO With attempts to ↓ use of PO corticosteroids Bronchodilator prn symptoms (short-acting B2 agonist)

Table 2
Categorization of severity of asthma

	Symptoms	Nocturnal symptoms	FEV1/PEFR
Stage 4 Severe persistent	Continuous	Frequent	<60% predicted variability >30%
Stage 3 Moderate persistent	Daily	>1 time a week	60-80% predicted variability >30%
Stage 2 Mild persistent	>1 time a week but <1time a day	>2 times a month	>80% predicted variability 20-30%
Stage 1 Intermittent	<1 time a week	<2 times a month	>80% predicted

Level of Asthma Control


Characteristic	Controlled (All of the ff)	Partly Controlled (Any measure present in any week)	Uncontrolled
Daytime symptoms	None (2x or <td>More than 2x/wk</td> <td>Three or more features of</td>	More than 2x/wk	Three or more features of
Limitations of activities	None	Any	partly controlled asthma present in any week
Nocturnal symptoms/ awakening	None	Any	III ally week
Need for reliever/rescue tx	None (2x or less/week)	More than 2x/ wk	
Lung function (PEF or FEV1)+	Normal	<80% predicted or personal best (if known)	
Exacerbations	None	One or more/ yr*	One in any wk‡

^{*}Any exacerbation should prompt review of maintenance treatment to ensure that it is adequate.

+ By definition, an exacerbation in any week makes that an uncontrolled asthma week.

‡ Lung function testing is not reliable for children 5 years and younger.





Adults & adolescents 12+ years

Personalized asthma management

Assess, Adjust, Review for individual patient needs



Confirmation of diagnosis if necessary Symptom control & modifiable risk factors (see Box 2-2B) Comorbidities Inhaler technique & adherence Patient preferences and goals



Treatment of modifiable risk factors and comorbidities Non-pharmacological strategies Asthma medications (adjust down/up/between tracks)

Education & skills training

CONTROLLER and PREFERRED RELIEVER

(Track 1). Using ICS-formoterol as reliever reduces the risk of exacerbations compared with using a SABA reliever

STEPS 1 - 2

STEP 1

SABA taken

Take ICS whenever

As-needed low dose ICS-formoterol

STEP 3

Low dose maintenance ICS-formoterol

STEP 4

Medium dose maintenance ICS-formoterol

STEP 5

Add-on LAMA Refer for assessment of phenotype. Consider high dose maintenance ICS-formoterol. ± anti-IgE, anti-IL5/5R, anti-IL4R, anti-TSLP

RELIEVER: As-needed low-dose ICS-formoterol

See GINA severe asthma guide

CONTROLLER and ALTERNATIVE RELIEVER

(Track 2). Before considering a regimen with SABA reliever, check if the patient is likely to be adherent with daily controller

Other controller options for either track (limited indications, or less evidence for efficacy or safety)

GINA 2022, Box 3-5A

STEP 2

Low dose maintenance ICS

STEP 3

Low dose maintenance ICS-LABA

STEP 4

Medium/high dose maintenance ICS-LABA

STEP 5

Add-on LAMA Refer for assessment of phenotype. Consider high dose maintenance ICS-LABA, ± anti-lgE, anti-IL5/5R, anti-IL4R. anti-TSLP

RELIEVER: As-needed short-acting beta2-agonist

Low dose ICS whenever SABA taken, or daily LTRA, or add HDM SLIT

Medium dose ICS, or add LTRA, or add HDM SLIT

Add LAMA or LTRA or HDM SLIT, or switch to high dose ICS

Add azithromycin (adults) or LTRA. As last resort consider adding low dose OCS but consider side-effects

© Global Initiative for Asthma, www.ginasthma.org

Part 4 DIFFERENCES BETWEEN B.A & COPD

Traditional Differences Between Asthma and COPD

Asthma

- Onset early in life
- Symptoms more variable within and between days
- Cough/Symptoms worse at night
- Post-exertional Wheezing/Dyspnea
- Allergic rhinitis and/or eczema also present
- Largely reversible airflow limitation

COPD

- Onset in midlife
- Symptoms slowly progresssive/ more consistent
- Cough/symptoms throughout the day
- Predominantly Exertional Dyspnea
- Long Smoking History
- Partially reversible airflow limitation

Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease—Updated 2003. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 2003. Available at: www.goldcopd.com/revised.pdf.

	Asthma	COPD
Age of onset	Usually <40 years	Usually >40 years
Smoking history	Not causal	Usually >10 pack-years
Sputum production	Infrequent	Often
Allergies	Often	Infrequent
Disease course	Stable (with	Progressive worsening
	exacerbations)	(with exacerbations)
Spirometry	Often normalizes	Never normalizes
Clinical symptoms	Intermittent and variable	Persistent

COPD Vs Asthma

	COPD	bronchial asthma
Smoker or ex-smoker	most	possibly
Symptoms under age 35	rare	common
Chronic productive cough	common	uncommon
breathlessness	Persistent and progressive	variable
Waking at night time with breathlessness or wheeze	uncommon	common
Significant diurnal or day to day variability of symptoms	Uncommon	common
FEV1 and FEV1/FVC ratio return to normal with drug therapy	Never with significant disease	probably



Global Initiative for Chronic Obstructive Lung Disease



POCKET GUIDE TO COPD DIAGNOSIS, MANAGEMENT, AND PREVENTION

A Guide for Health Care Professionals

2022 REPORT